Want to see SONX full AI Analyst Report?
Sonendo (SONX) AI Stock Analysis
Sonendo
(Other OTC:SONX)
SONX scores in the low range, driven primarily by a distressed financial profile: two consecutive years of revenue decline, continued net losses, negative stockholders' equity, and a total asset base that has shrunk to $18.8M, raising meaningful going-concern and dilution risk. Improving gross margins (above 40%) and a sharply reduced cash burn (-$11M versus -$62M in 2022) show real cost discipline and prevent a lower score. Technicals are the strongest element, with the stock trading well above all major moving averages and momentum indicators still in neutral territory, indicating sustained investor interest. Valuation, however, provides no cushion given negative earnings, no dividend, and negative book value. This remains a high-risk, speculative situation where price strength is running ahead of fundamentals.
Sonendo (SONX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $547.07K
- Dividend Yield
- ―
- Average Volume (3M)
- 760
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- -0.54
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 130
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Sonendo Business Overview & Revenue Model
Company Description
Sonendo, Inc. operates as a commercial-stage medical technology firm, dedicated to innovating, producing, and marketing advanced devices for root canal treatment across the United States and Canada. A flagship offering is GentleWave, an innovative de...
How the Company Makes Money
Sonendo makes money primarily by selling (1) capital equipment and (2) recurring procedure-related consumables associated with the GentleWave System. The capital equipment stream comes from the sale of the GentleWave console/system placed in dental p...
Sonendo Earnings Call Summary
The earnings call for Sonendo reflects a positive sentiment overall, with significant improvements in gross margins, operating expenses, and adjusted EBITDA loss, despite challenges in PI sales and total revenue decline. The company is optimistic about its strategic reset and future growth prospects.
Q2-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the Sonendo Q2 2024 earnings call, the company provided updated guidance and highlighted several key metrics illustrating their progress. Sonendo raised their full-year 2024 revenue guidance to a range of $31 million to $32 million, up from the previous $29 million to $31 million. They reported a significant improvement in gross margins, with adjusted gross margin increasing to 40.7% in Q2 2024 from 28.7% in the prior year quarter. The company also achieved a 53% reduction in year-over-year adjusted EBITDA loss, reporting a loss of $5.7 million for the quarter. Sonendo's strategic reset focused on commercial execution, gross margin expansion, and cash conservation, with a notable 42% reduction in operating expenses compared to the prior year. Despite a decrease in PI sales by 15% year-over-year, the company emphasized stabilizing utilization rates and anticipates low single-digit growth in PI sales for the second half of the year. Additionally, Sonendo aims to achieve adjusted gross margins in the 40% to 41% range for the latter half of 2024, with long-term aspirations of reaching 60% as they continue to enhance their operational and financial performance.
Sonendo Financial Statement Overview
Summary
Sonendo's financials are severely distressed. Revenue fell ~10% to $28.6M after a ~28% decline the prior year, leaving the top line below 2020 levels, while net losses persist (-$14.4M). The balance sheet is the biggest red flag: stockholders' equity has turned negative (-$2.3M), total assets have collapsed from $137M to $18.8M, and $16.2M of debt sits against that shrinking asset base, pointing to going-concern risk. The partial offsets — gross margins above 40% and cash burn narrowed from -$46M to -$11M — buy time but do not resolve the core issue of declining revenue and depleted capital.
Income Statement
12Very NegativeBalance Sheet
6Very NegativeCash Flow
15Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.70M | 28.55M | 31.70M | 43.87M | 41.66M | 33.20M |
| Gross Profit | 11.84M | 11.97M | 11.84M | 10.72M | 10.48M | 8.34M |
| EBITDA | -27.36M | -12.62M | -26.61M | -54.77M | -51.00M | -41.29M |
| Net Income | -28.03M | -14.41M | -28.03M | -60.92M | -57.05M | -48.50M |
Balance Sheet | ||||||
| Total Assets | 31.27M | 18.84M | 31.27M | 78.16M | 137.28M | 115.50M |
| Cash, Cash Equivalents and Short-Term Investments | 11.63M | 5.01M | 11.63M | 46.78M | 91.45M | 84.64M |
| Total Debt | 18.93M | 16.16M | 18.93M | 40.35M | 38.99M | 29.33M |
| Total Liabilities | 26.07M | 21.15M | 26.07M | 49.74M | 55.33M | 43.44M |
| Stockholders Equity | 5.19M | -2.32M | 5.19M | 28.42M | 81.95M | 72.06M |
Cash Flow | ||||||
| Free Cash Flow | -24.81M | -11.02M | -24.81M | -46.99M | -62.43M | -50.58M |
| Operating Cash Flow | -24.65M | -11.02M | -24.65M | -46.06M | -61.07M | -48.60M |
| Investing Cash Flow | 45.81M | 2.40M | 45.81M | 42.40M | -74.43M | -1.97M |
| Financing Cash Flow | -24.95M | 3.41M | -24.95M | 4,000 | 68.53M | 83.50M |
Sonendo Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SONX, the sentiment is Positive. The current price of 1.28 is above the 20-day moving average (MA) of 1.27, above the 50-day MA of 1.20, and above the 200-day MA of 0.65, indicating a bullish trend. The MACD of 0.03 indicates Positive momentum. The RSI at 54.87 is Neutral, neither overbought nor oversold. The STOCH value of is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SONX.
Sonendo Risk Analysis
Sonendo disclosed 85 risk factors in its most recent earnings report. Sonendo reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksSonendo Peers Comparison
Overall Rating
- SONX49Neutral
COCH44Neutral
ECOR44Neutral
MOVE43Neutral
LFWD42Neutral
PAVM40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SONX | 49Neutral | $547.07K | -0.42 | -1003.06% | ― | ― | ― |
| COCH | 44Neutral | $51.31M | -0.99 | 1719.71% | ― | -6.76% | 42.70% |
| ECOR | 44Neutral | $67.80M | -4.21 | 524.69% | ― | 33.45% | 0.24% |
| MOVE | 43Neutral | $210.77M | -0.51 | -9.67% | ― | 843.62% | 21.98% |
| LFWD | 42Neutral | $16.86M | -0.36 | -310.86% | ― | -10.68% | 55.33% |
| PAVM | 40Underperform | $15.59M | -0.12 | -33.51% | ― | -89.02% | -107.75% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SONX | Sonendo Inc | 1.28 | 1.02 | 392.31% | |
| LFWD | Lifeward Ltd. | 6.06 | -0.58 | -8.76% | |
| ECOR | Electrocore | 7.16 | 2.21 | 44.65% | |
| PAVM | Pavmed | 1.91 | -9.37 | -83.07% | |
| MOVE | Corvex, Inc. | 6.22 | 2.39 | 62.44% | |
| COCH | Envoy Medical, Inc. Class A | 6.65 | -0.60 | -8.30% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 08, 2026